Phaseline

Targets › ITGB7

ITGB7 (Integrin beta-7): drug programs, companies and trials

7 programs from 7 companies in 49 trials: 17 Phase 3, 17 Phase 2, 11 Phase 4, 4 Phase 1; Immunology, Oncology, Neurology; next expected readout Dec 2026.

Integrin ITGA4/ITGB7 (alpha-4/beta-7) (Peyer patches-specific homing receptor LPAM-1) is an adhesion molecule that mediates lymphocyte migration and homing to gut-associated lymphoid tissue (GALT) (Probable). Integrin ITGA4/ITGB7 interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. (UniProt, P26010)

Open in Phaseline: the race on ITGB7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaVedolizumab
Integrin alpha-4/beta-7 inhibitor
ITGA4, ITGB7Phase 4Ulcerative Colitis; Crohn's Disease; Crohn's Disease (CD); Moderately to Severely Active Ulcerative Colitis …May 2027
The Cleveland ClinicNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 4Multiple Sclerosis, Relapsing-RemittingJul 2027
RocheAfimkibart
Anti-integrin α4β7 monoclonal antibody
ITGA4, ITGB7, IL22RA1Phase 3Moderately to Severely Active Ulcerative Colitis; Moderately to Severely Active Crohns Disease; Crohns Disease; Atopic Dermatitis …Dec 2026
Queen Mary University of LondonNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 2Multiple SclerosisOct 2027
University of Michigan Rogel Cancer CenterNatalizumab
Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor
ITGA4, ITGB7, ITGB1Phase 2Recurrent Diffuse Large B-Cell LymphomaMay 2028
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)MORF-057
Selective integrin α4β7 inhibitor
ITGA4, ITGB7Phase 2Inflammatory Bowel DiseasesSep 2028
7 Hills PharmaAlintegimod
α4β7 integrin antagonist
ITGA4, ITGB7Phase 1Advanced CancerDec 2027

Conditions

Ulcerative Colitis (11) Moderately to Severely Active Ulcerative Colitis (5) Crohn's Disease (4) Moderately to Severely Active Crohns Disease (3) Crohn Disease (2) Acute Lymphoblastic Leukemia (2) Atopic Dermatitis (2) Rheumatoid Arthritis (2) Inflammatory Bowel Diseases (2) Crohn's Disease (CD) (1) Pouchitis (1) Moderately to Severely Active Crohn's Disease (1)

Modalities

antibody (3), mixed (3), small molecule (1)

Companies

Takeda (1) Roche (1) University of Michigan Rogel Cancer Center (1) Queen Mary University of London (1) 7 Hills Pharma (1) The Cleveland Clinic (1) Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) (1)

Related targets

ITGA4 (7) ITGB1 (3) IL22RA1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.